MY-008 is under clinical development by Createrna Science and Technology and currently in Phase I for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase I drugs for IgA Nephropathy (Berger’s Disease) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MY-008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MY-008 overview
MY-008 is under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy. It is administered through oral route as tablet. The drug candidate acts by targeting complement factor B (CFB).
Createrna Science and Technology overview
Createrna Science and Technology is a pharmaceutical and healthcare company that is involved in development of disposable infusion filters. The company is headquartered in Wuhan, Hubei, China.
For a complete picture of MY-008’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
